We describe the case of a HBsAg þ , HBeAg þ carrier, treated with lamivudine, who experienced exacerbation of hepatitis after BMT from an anti-HBs þ , anti-HBc þ , anti-HBe þ donor. The serological profile of the donor and the timing of exacerbation suggested that the adoptive immunity transfer played a major pathogenetic role. Antilymphocyte globulin administration resulted in resolution of hepatitis and seroconversion to anti-HBs þ . Therapy aimed at blocking the effector arm of liver damage could represent a novel approach to avoid the risk of progression to fulminant hepatitis without hampering the chances of recovery from hepatitis B.
Chronic or de novo acquired Hepatitis B virus (HBV) infection cause significant morbidity and mortality after bone marrow transplantation (BMT). Previous reports showed that the incidence of hepatitis is significantly higher in HBsAg-positive as compared to HBsAg-negative recipients. 1 The major cause of such cases is HBV reactivation, 2 that may result in hepatic failure or death. On the basis of these observations and the availability of antiviral drugs, in the last years the treatment of HBsAg carriers with nucleoside analogs before and after BMT has been proposed. 3 Preliminary reports suggest that antiviral therapy may reduce the incidence of post-BMT HBV reactivation and hepatitis. Nevertheless, some patients still develop HBVrelated complications. 3 Therefore, antiviral treatment should be optimized and alternative therapeutic strategies explored if hepatitis B reactivates. 4 The role of the adoptive transfer of specific anti-HBV immunity into a HBV carrier via a HBVimmune donor should also be studied in terms of HBV clearance and risk of hepatitis B exacerbation. 5 
Case report
In May 1999, a 5-year-old girl with acute lymphoblastic leukemia (ALL) in second complete remission (CR) was referred from Venezuela to our institution for allogeneic bone marrow transplant (BMT) from her 7-year-old human leucocyte antigen (HLA)-identical brother.
The patient was a chronic HBV carrier (HBsAg þ , HBeAg þ ), and had detectable levels of HBV-DNA (1 Â 10 6 copies/ml, detected by Monitor HBV, Roche, UK). She was IgM anti-HBc þ [IMx Index 0.44 (by Core-M assay, Abbott Laboratories, North Chicago, IL, USA] using 0.200 IMx Index as chronic hepatitis cut-off and 0.100-0.200 IMx Index values as 'chronic hepatitis gray zone'. 6 ALT was 50 U/l. Her brother was anti-HBs þ (3900 IU/ml), anti-HBc þ , and anti-HBe þ , had no detectable HBV-DNA and had normal liver enzyme (AST 27 U/l, ALT 31 U/l). The patient started antiviral therapy with lamivudine (75 mg/day) and maintenance chemotherapy (6-mercaptopurine, methotrexate, and intrathecal Ara-C þ methotrexate þ steroids). During treatment, HBV-DNA and IgM anti-HBc levels progressively decreased, HBV-DNA levels felt below the sensitivity limits of the assay (o400 copies/ml) after 6 months, and IgM anti-HBc reduced to 0.22 IMX Index. Transaminases were normal and HBsAg and HBeAg remained detectable.
She was allografted after 6 months of lamivudine after cyclophosphamide 120 mg/kg; thiotepa 10 mg/kg, and TBI 12 Gy (in six fractions) followed by i.v. infusion of unmanipulated bone marrow (5.9 Â 10 8 mononuclear cells/ kg) from her brother. Cyclosporine was used to prevent graft-versus-host disease (GVHD), and fluconazole, ciprofloxacin, acyclovir, and lamivudine administered prophylactically.
Fever developed on day 13 with elevation of transaminases (AST 104 U/l and ALT 110 U/l); Alkaline phosphatase, bilirubin, and prothrombin time were normal. Liver and spleen were not enlarged. The patient showed some signs of engraftment on day 15, when HBV-DNA (4000 copies/ml) and IgM anti-HBc (Imx Index 1.3) were detectable. On day 16, liver enzymes were significantly increased (AST 1574 U/l; ALT 1568 U/l); with bilirubin 1.7 mg/dl, PT 52% (normal 70-100%), INR 1.57 (normal 0.9-1.15), and PTT 50 s (normal 25-40 s). Liver was palpable 4 cm beneath the costal margin. HBV-DNA level reached 8000 copies/ml.
No clinical manifestations of GVDH or VOD were seen. CMV antigenemia was negative and blood cyclosporine level was within the normal range. Ganciclovir (10 mg/kg/ day) was added as antiviral therapy, and horse ALG (SangStat Medical Corporation, 1.5 vials/10 kg/day Â 5 days, then on alternate days up to day 29) and Mycophenolate (250 mg/day until day 58) were administered as immunosuppressive therapy.
From day 17 transaminases levels decreased progressively, reaching normal values on day 44. On day 27, the liver became impalpable. On day 30, HBV-DNA was o400 copies/ml and IgM anti-HBc was 2.6 IMX values; their levels decreased thereafter (on day 60: IgM anti-HBc 1.2 IMX values; on day 90: IgM anti-HBc 0.8 IMX values) and on day 90 anti-HBe antibodies were detectable (Figure 1) . At 10 months post-BMT, transaminases were within the normal range, and HBsAg was negative and antiHBs was positive. Full engraftment was seen on day 28.
Discussion
Our patient, despite significant inhibition of a chronic HBV infection with lamivudine, experienced severe hepatitis B exacerbation 15 days after BMT from an anti-HBs, anti-HBc, anti-HBe positive donor. The severity of the hepatitis flare was controlled by immunosuppressive therapy specifically targeted to block activated lymphocytes (ALG).
Severe hepatitis B exacerbations may be life-threatening in HBV carriers undergoing BMT. Usually, hepatitis flares are observed a few months after BMT during tapering of immunosuppressive drugs, and are preceded by a significant increase of HBV-DNA levels (and reappearance of serum HBeAg in anti-HBe carriers). These events suggest that HBV reactivation, induced by immunosuppressive therapy, plays a major role in the hepatitis B exacerbation. In our patient, the hepatitis flare occurred early and without a significant increase in serum HBV-DNA.
Marked elevation of liver enzymes early after BMT is rare. A review from the Seattle group reported a severe hepatocellular injury in 1.8% of cases within first 100 days after transplant. 7 No case of HBV hepatitis was observed. The main cause of marked AST elevation early after BMT (day 2379) was VOD. Our patients did not have any clinical evidence of VOD. The other two possible etiologies, varicella zoster (VZV) hepatitis and ischemic hepatopathy, were not consistent with the clinical and biochemical profile of our patient. Also, the patient was on acyclovir which would have prevented VZV reactivation. Ischemic hepatopathy usually occurs with sepsis, cardiogenic shock, or multiorgan failure, all absent in our patient.
The Horse antilymphocytic globulin in hepatitis B after BMT C Favre et al suggests that the adoptive immunity transfer possibly played a role in the exacerbation of hepatitis. Our patient had ongoing HBV replication and serum HBeAg at the time of BMT. A florid expression of viral antigens at the hepatocyte level could have favoured a rapid recruitment of activated lymphocytes within the liver at the time of bone marrow recovery. The sudden liver enlargement, brisk ALT elevation, and deranged coagulation suggested a high risk of severe progression of liver damage prompting a strong immunosuppressive therapy. Rapid improvement of both clinical and biochemical parameters was seen after ALG was started. Clearance of serum HBV-DNA with HBeAg to anti-HBe and HBsAg to anti-HBs seroconversion suggests that the inhibition of T-cell activity did not abrogate the effectiveness of the immune control of HBV infection. The evidence that ALG were able to block the progression of liver damage without compromising both the recovery from hepatitis B and the seroconversion to anti-HBs is in accordance with studies in animal models and preliminary reports in humans suggesting that nonspecific T-cell recruitment plays a major role in the pathogenesis of liver damage. [8] [9] Recently, Guidotti et al 8 showed in chimpanzees that during primary HBV infection, liver damage occurs after the clearance of HBV and concomitantly with the massive infiltration of CD8 cells that is unlikely to be composed primarily of HBV-specific CD8 cells. In addition, using transgenic mice as recipients of HBV-specific cytotoxic T lymphocytes, liver damage was demonstrated to be due to the recruitment of lymphomononuclear cells into the liver, as a consequence of chemokines production by hepatocytes and other nonparenchymal cells. 10 The finding that the neutralization of these chemokines is associated with maintenance of antiviral effects but diminished tissue damage suggests that an alternative therapy, aimed to block the effector arm of hepatocellular injury, could represent an effective approach to avoid the risk of progression, without hampering the chances of immune recovery from hepatitis B.
